XML 36 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Segments of Business and Geographic Areas
 3 Months Ended
Apr. 03, 2022
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS
SALES BY SEGMENT OF BUSINESS
 Fiscal First Quarter Ended
(Dollars in Millions)April 3,
2022		April 4,
2021		Percent
Change
CONSUMER HEALTH   
OTC(1)
     U.S.$670 599 11.8 %
     International791 673 17.5 
     Worldwide 1,461 1,273 14.8 
Skin Health/Beauty
     U.S.544 634 (14.2)
     International468 529 (11.6)
     Worldwide 1,012 1,163 (13.0)
Oral Care
     U.S.143 163 (12.6)
     International223 254 (12.0)
     Worldwide 366 417 (12.2)
Baby Care
     U.S.85 96 (11.5)
     International270 293 (7.7)
     Worldwide 355 389 (8.6)
Women's Health
     U.S.3 3 7.2 
     International224 219 2.5 
     Worldwide 228 222 2.6 
Wound Care/Other
     U.S.112 115 (3.3)
     International52 61 (15.3)
     Worldwide 164 177 (7.4)
TOTAL CONSUMER HEALTH
     U.S.1,557 1,611 (3.4)
     International2,029 2,030 0.0
     Worldwide 3,586 3,641 (1.5)
PHARMACEUTICAL
Immunology
     U.S.2,501 2,413 3.7 
     International1,617 1,501 7.7 
     Worldwide 4,119 3,914 5.2 
     REMICADE
     U.S.358 489 (26.8)
     U.S. Exports80 57 40.5 
     International225 232 (2.6)
     Worldwide 663 777 (14.7)
     SIMPONI / SIMPONI ARIA
     U.S.287 255 12.5 
     International283 307 (7.6)
     Worldwide 571 562 1.5 
     STELARA
     U.S.1,379 1,331 3.6 
     International909 817 11.2 
     Worldwide 2,288 2,148 6.5 
     TREMFYA
     U.S.391 274 42.7 
     International199 143 38.8 
     Worldwide 590 418 41.3 
     OTHER IMMUNOLOGY
     U.S.6 7 (3.2)
     International0 2 *
     Worldwide 6 8 (22.0)
Infectious Diseases
     U.S.461 512 (10.0)
     International836 485 72.3 
     Worldwide 1,297 998 30.0 
     COVID-19 VACCINE
     U.S.75 100 (24.9)
     International382 0*
     Worldwide457 100 *
     EDURANT / rilpivirine
     U.S.9 10 (12.6)
     International239 233 2.5 
     Worldwide 248 243 1.8 
      PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     U.S.369 380 (3.1)
     International132 166 (20.3)
     Worldwide 501 546 (8.3)
     OTHER INFECTIOUS DISEASES(1)
     U.S.8 21 (62.5)
     International83 87 (3.8)
     Worldwide 91 108 (15.3)
Neuroscience
     U.S.843 771 9.3 
     International898 943 (4.8)
     Worldwide 1,741 1,715 1.5 
     CONCERTA / methylphenidate
     U.S.35 47 (26.5)
     International122 123 (1.3)
     Worldwide 157 171 (8.3)
     INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
     U.S.661 589 12.2 
     International387 376 3.0 
     Worldwide 1,048 965 8.6 
     RISPERDAL CONSTA
     U.S.63 67 (6.4)
     International66 89 (26.1)
     Worldwide 129 157 (17.6)
     OTHER NEUROSCIENCE(1)
     U.S.84 67 25.5 
     International323 355 (8.9)
     Worldwide 408 422 (3.5)
Oncology
     U.S.1,582 1,377 14.9 
     International2,369 2,193 8.0 
     Worldwide 3,950 3,570 10.6 
     DARZALEX
     U.S.953 691 37.9 
     International903 674 34.0 
     Worldwide 1,856 1,365 36.0 
     ERLEADA
     U.S.206 171 20.3 
     International194 90  *
     Worldwide 400 261 53.0 
     IMBRUVICA
     U.S.370 444 (16.7)
     International668 680 (1.8)
     Worldwide 1,038 1,125 (7.7)
     ZYTIGA / abiraterone acetate
     U.S.19 50 (62.1)
     International520 588 (11.6)
     Worldwide 539 638 (15.6)
     OTHER ONCOLOGY
     U.S.34 21 63.1 
     International84 161 (47.7)
     Worldwide 118 182 (35.1)
Pulmonary Hypertension
     U.S.572 573 (0.2)
     International279 288 (2.9)
     Worldwide 852 861 (1.1)
     OPSUMIT
     U.S.273 272 0.5 
     International170 179 (4.8)
     Worldwide 443 450 (1.6)
     UPTRAVI
     U.S.269 259 3.9 
     International56 46 20.9 
     Worldwide 325 305 6.5 
     OTHER PULMONARY HYPERTENSION
     U.S.30 42 (29.0)
     International53 63 (15.2)
     Worldwide 83 105 (20.8)
Cardiovascular / Metabolism / Other
     U.S.672 799 (15.8)
     International238 245 (3.0)
     Worldwide 910 1,044 (12.8)
     XARELTO
     U.S.508 589 (13.8)
     International— — — 
     Worldwide 508 589 (13.8)
     INVOKANA / INVOKAMET
     U.S.60 87 (30.7)
     International68 63 7.5 
     Worldwide 128 150 (14.6)
     OTHER(1,2)
     U.S.104 122 (14.9)
     International170 182 (6.6)
     Worldwide 274 305 (10.0)
TOTAL PHARMACEUTICAL  
     U.S.6,632 6,446 2.9 
     International6,237 5,655 10.3 
     Worldwide 12,869 12,101 6.3 
MEDTECH(3)
Interventional Solutions
     U.S.494 434 13.8 
     International597 514 16.2 
     Worldwide 1,092 949 15.1 
Orthopaedics
     U.S.1,289 1,249 3.2 
     International899 864 4.1 
     Worldwide 2,188 2,113 3.5 
     HIPS
     U.S.225 209 7.3 
     International164 146 12.2 
     Worldwide 389 356 9.3 
     KNEES
     U.S.201 185 8.6 
     International138 132 4.1 
     Worldwide 339 317 6.7 
     TRAUMA
     U.S.475 450 5.5 
     International273 282 (3.3)
     Worldwide 748 733 2.1 
     SPINE, SPORTS & OTHER
     U.S.387 404 (4.1)
     International324 303 7.0 
     Worldwide 712 707 0.6 
Surgery
     U.S.921 898 2.5 
     International1,513 1,474 2.7 
     Worldwide 2,434 2,372 2.6 
     ADVANCED
     U.S.417 405 3.0 
     International729 713 2.2 
     Worldwide 1,146 1,118 2.5 
     GENERAL
     U.S.504 493 2.1 
     International784 761 3.1 
     Worldwide 1,288 1,254 2.7 
Vision
     U.S.521 472 10.4 
     International736 673 9.4 
     Worldwide 1,257 1,145 9.8 
     CONTACT LENSES / OTHER
     U.S.400 371 7.7 
     International511 486 5.1 
     Worldwide 910 857 6.2 
     SURGICAL
     U.S.121 101 20.2 
     International226 187 20.5 
     Worldwide 347 288 20.4 
TOTAL MEDTECH  
     U.S.3,225 3,054 5.6 
     International3,746 3,525 6.3 
     Worldwide 6,971 6,579 5.9 
WORLDWIDE   
     U.S.11,414 11,111 2.7 
     International12,012 11,210 7.2 
     Worldwide $23,426 22,321 5.0 %
*Percentage greater than 100% or not meaningful
(1) In the fiscal first quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
(2) Inclusive of PROCRIT / EPREX which was previously disclosed separately
(3) Previously referred to as Medical Devices

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*
 Fiscal First Quarter Ended
(Dollars in Millions)April 3,
2022		April 4,
2021		Percent
Change
Consumer Health (1)
$686 842 (18.5)%
Pharmaceutical(2)
3,924 5,169 (24.1)
MedTech(3)
1,477 1,629 (9.3)
Segment earnings before provision for taxes6,087 7,640 (20.3)
Less: Expense not allocated to segments (4)
123 211  
Less: Consumer Health separation costs 102 — 
Worldwide income before tax$5,862 7,429 (21.1)%
*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
(1) Consumer Health includes:
•Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021
(2) Pharmaceutical includes:
•Divestiture gains of $0.6 billion in the fiscal first quarter of 2021 related to two brands outside the U.S.
•Intangible amortization expense of $0.8 billion and $0.9 billion in the fiscal first quarter of 2022 and 2021, respectively
•In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.
•A loss of $0.4 billion related to the change in the fair value of securities in the fiscal first quarter of 2022

In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities
accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.

(3) MedTech includes:
•A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021
•Intangible amortization expense of $0.3 billion in both the fiscal first quarter of 2022 and 2021

(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.

SALES BY GEOGRAPHIC AREA
 Fiscal First Quarter Ended
(Dollars in Millions)April 3, 2022April 4, 2021Percent
Change
United States$11,414 11,111 2.7 %
Europe6,024 5,414 11.3 
Western Hemisphere, excluding U.S.1,482 1,424 4.1 
Asia-Pacific, Africa4,506 4,372 3.1 
Total$23,426 22,321 5.0 %